NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
How does the micro-cap biotech now finance a 700-patient phase 3 study?
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
